Nectar Lifesciences Ltd.

•

neclife.comBSE: 532649NSE: NECLIFE

Market Cap₹ 223 Cr.

Current Price

High / Low₹ 22 / 9

Stock P/E13.4

Book Value₹ 29

Price to Book0.31

Dividend Yield0.00 %

ROCE-4.8 %

ROE-7.5 %

Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company is almost debt free
Company generates healthy free cash flow

CONS

Company is loss-making at the operating / net level
Operating cash flow has been negative in recent years
Company has a low return on equity of -2.3% over last 3 years
Company has a low return on capital employed of 0.8%
Interest coverage is weak at -1.3x - earnings barely cover interest
Promoter holding has decreased over last 2 years: -4.0pp

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	NECLIFE	11.50	13.43	223.40	0.00	-15.40	75.65	0.44	-99.84	-4.75	-6170.14

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	394	398	452	440	359	6	0	0	281	5	0	0	0
	359	371	410	393	320	6	0	0	343	6	2	59	28
Operating Profit	36	27	42	47	39	-1	-0	-0	-62	-1	-2	-59	-28
OPM %	9.02%	6.75%	9.33%	10.68%	10.97%	-10.30%	—	—	-22.05%	-20.80%	—	—	-6223.53%
	0	11	0	1	1	1	0	0	0	0	89	6	6
Interest	18	21	25	24	20	0	0	0	19	0	30	6	0
Depreciation	15	15	15	15	15	0	0	0	17	0	0	0	0
Profit before Tax	3	2	2	11	5	-0	0	-0	-97	-1	57	-57	-22
Tax %	40.52%	38.41%	36.33%	94.60%	39.63%	34.29%	34.29%	37.50%	34.64%	35.29%	-19.49%	34.63%	37.86%
Net Profit	2	1	2	1	3	-0	0	-0	-63	-0	68	-37	-13
	0.08	0.05	0.07	0.03	0.13	-0.01	0.01	-5.80	-2.82	-0.01	3.02	-3.38	-0.68

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	1,643	1,876	2,785	2,363	1,542	1,668	1,524	1,684	0	0	5
	1,419	1,639	2,521	2,145	1,440	1,509	1,469	1,533	0	61	94
Operating Profit	224	236	264	218	102	159	55	152	-0	-61	-89
OPM %	13.64%	12.59%	9.48%	9.23%	6.59%	9.52%	3.59%	9.00%	—	—	-1635.39%
	23	6	6	4	-14	11	53	27	10	11	101
Interest	117	115	148	126	112	79	89	99	9	37	36
Depreciation	62	64	63	61	60	57	59	61	1	0	0
Profit before Tax	67	63	59	36	-85	34	-41	18	1	-88	-22
Tax %	17.97%	16.64%	19.16%	15.90%	13.59%	26.29%	44.81%	72.63%	34.98%	34.74%	173.98%
Net Profit	55	52	47	30	-73	25	-22	5	1	-57	17
EPS	2.46	2.33	2.11	1.34	-3.26	1.13	-1.00	0.22	0.03	-2.95	—
Dividend Payout %	2.03%	2.15%	2.37%	3.73%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	—

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

STOCK PRICE CAGR

10 Years:: -11%
5 Years:: -17%
3 Years:: -23%
1 Year:: -23%

RETURN ON EQUITY

10 Years:: 0%
5 Years:: -1%
3 Years:: -2%
Last Year:: -7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	22	22	22	22	22	22	22	22	22	19
	984	1,036	1,082	1,112	1,038	1,064	1,042	1,047	934	563
	897	973	916	781	906	795	755	553	501	0
Trade Payables	528	539	483	527	342	377	319	420	438	0
	149	153	201	189	66	128	31	141	97	-194
Total Liabilities	2,581	2,724	2,704	2,632	2,375	2,387	2,169	2,184	1,992	388
	881	852	825	785	772	723	662	643	633	3
Capital Work in Progress	102	100	100	115	99	85	78	66	57	0
	1	1	1	1	1	1	1	1	1	13
	854	859	915	975	587	660	673	709	690	0
	0	0	0	0	0	0	0	379	345	0
Cash & Bank	13	9	21	21	25	18	18	20	19	108
	730	902	843	735	891	901	738	366	247	263
Total Assets	2,581	2,724	2,704	2,632	2,375	2,387	2,169	2,184	1,992	388

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	206	78	252	295	25	95	133	225	169	-417
Cash from Investing	-18	-29	-26	-33	-29	17	52	-17	-42	1,205
Cash from Financing	-204	-40	-201	-252	11	-119	-186	-205	-128	-699
	-24	-4	12	1	4	-8	-0	2	-1	89

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
55.80	55.80	44.53	44.53	44.53	44.91	44.91	51.84	51.84
16.60	3.24	0.73	1.65	0.82	0.62	0.52	0.60	0.50
0.00	0.00	0.00	0.13	0.13	0.04	0.00	0.00	0.00
0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
27.57	40.94	54.72	53.67	54.50	54.41	48.73	43.52	43.90

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-08-22

General Updates

2026-08-22 - Please find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015.

2026-08-21

Copy of Newspaper Publication

2026-08-21 - Please find attached herewith newspaper publication of notice of 31st Annual General Meeting, e-voting, book closure & other information.

2026-08-20

Shareholders meeting

2026-08-20 - Nectar Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 18, 2026

2026-08-20

Copy of Newspaper Publication

2026-08-20 - Please find attached herewith newspaper publication of notice to the shareholders regarding 31st AGM of the Company to be held on Friday, September 18, 2026, through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM), and other information as required under circulars issued by Ministry of Corporate Affairs

2026-08-15

Copy of Newspaper Publication

2026-08-15 - Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-15

General Updates

2026-08-15 - Nectar Lifesciences Limited has informed the Exchange about change in corporate office of the Company

2026-08-14

Record Date

2026-08-14 - Nectar Lifesciences Limited has informed the Exchange that Record date for the purpose of ascertaining the eligibility of members for remote e-voting and/ or polling/ e-voting at 31st AGM is 11-Sep-2026

2026-08-14

Outcome of Board Meeting

2026-08-14 - We wish to inform you that the board of directors of Nectar Lifesciences Limited ( Company ) in their meeting held on August 14, 2026, have, inter-alia, noted, decided and approved the following matters:1. Appointed Dr. Gunmala Suri (DIN: 11879344) as an Additional Director from August 15, 2026, till forthcoming Annual General meeting ( AGM ) as well as Non-Executive Non-Independent Director subject to approval of members at the forthcoming AGM of the Company with effect from August 15, 2026;2. To convene the 31st AGM of the members of the Company on Friday, September 18, 2026;3. To close the register of members and share transfer books from September 12, 2026, to September 18, 2026 (both days inclusive) for the purpose of AGM. Accordingly, the cut-off date, to ascertain the eligibility of members for remote e-voting and polling/ e-voting at AGM, is September 11, 2026, i.e., the date prior to the commencement of book closure;4. The re-appointment of Mr. Sanjiv Goyal (DIN: 00002841), director, who retire by rotation, in the forthcoming AGM;and5.. The proposal for appointment of Dr. Gunmala Suri (DIN: 11879344) as a regular director as well as Non-Executive Non-Independent Director with effect from August 15, 2026, subject to approval of the members at the forthcoming AGM.

2026-08-14

Outcome of Board Meeting

2026-08-14 - Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

News

Recent coverage and analyst commentary for NECLIFE

Loading news…

🤖

AI Stock Analyst

Nectar Lifesciences Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1842.00

36.54

441957.50

0.87

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9326.00

84.64

247576.00

0.32

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4975.00

86.76

189233.01

0.76

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1119.50

24.74

111670.55

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1365.00

32.72

110272.68

0.95

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1970.35

97.37

106460.42

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

DRREDDY

1161.00

30.07

96906.38

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

AUROPHARMA

1675.45

25.97

96401.69

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2096.00

17.34

95842.92

0.86

1416.98

16.01

8276.89

34.28

28.86

29.59

MANKIND

2277.00

46.04

94050.37

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2416.90

37.94

68210.88

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

NECLIFE

11.50

13.43

223.40

0.00

-15.40

75.65

0.44

-99.84

-4.75

-6170.14

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

394

398

452

440

359

281

359

371

410

393

320

343

Operating Profit

-1

-0

-62

-1

-2

-59

-28

OPM %

9.02%

6.75%

9.33%

10.68%

10.97%

-10.30%

—

-22.05%

-20.80%

—

-6223.53%

Interest

Depreciation

Profit before Tax

-0

-97

-1

-57

-22

Tax %

40.52%

38.41%

36.33%

94.60%

39.63%

34.29%

37.50%

34.64%

35.29%

-19.49%

34.63%

37.86%

Net Profit

-0

-63

-0

-37

-13

0.08

0.05

0.07

0.03

0.13

-0.01

0.01

-5.80

-2.82

-0.01

3.02

-3.38

-0.68

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

TTM

1,643

1,876

2,785

2,363

1,542

1,668

1,524

1,684

1,419

1,639

2,521

2,145

1,440

1,509

1,469

1,533

Operating Profit

224

236

264

218

102

159

152

-0

-61

-89

OPM %

13.64%

12.59%

9.48%

9.23%

6.59%

9.52%

3.59%

9.00%

—

-1635.39%

-14

101

Interest

117

115

148

126

112

Depreciation

Profit before Tax

-85

-41

-88

-22

Tax %

17.97%

16.64%

19.16%

15.90%

13.59%

26.29%

44.81%

72.63%

34.98%

34.74%

173.98%

Net Profit

-73

-22

-57

EPS

2.46

2.33

2.11

1.34

-3.26

1.13

-1.00

0.22

0.03

-2.95

—

Dividend Payout %

2.03%

2.15%

2.37%

3.73%

0.00%

—

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Equity Capital

984

1,036

1,082

1,112

1,038

1,064

1,042

1,047

934

563

897

973

916

781

906

795

755

553

501

Trade Payables

528

539

483

527

342

377

319

420

438

149

153

201

189

128

141

-194

Total Liabilities

2,581

2,724

2,704

2,632

2,375

2,387

2,169

2,184

1,992

388

881

852

825

785

772

723

662

643

633

Capital Work in Progress

102

100

115

854

859

915

975

587

660

673

709

690

379

345

Cash & Bank

108

730

902

843

735

891

901

738

366

247

263

Total Assets

2,581

2,724

2,704

2,632

2,375

2,387

2,169

2,184

1,992

388

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

206

252

295

133

225

169

-417

Cash from Investing

-18

-29

-26

-33

-29

-17

-42

1,205

Cash from Financing

-204

-40

-201

-252

-119

-186

-205

-128

-699

-24

-4

-8

-0

-1

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

55.80

44.53

44.91

51.84

16.60

3.24

0.73

1.65

0.82

0.62

0.52

0.60

0.50

0.00

0.13

0.04

0.00

0.02

27.57

40.94

54.72

53.67

54.50

54.41

48.73

43.52

43.90

Nectar Lifesciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Nectar Lifesciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI